

1 **Polymer functionalized gold nanoparticles as non-viral gene delivery reagents**

2 M. Mar Encabo-Berzosa^{†,□,‡}, Maria Sancho-Albero^{†,□,‡}, Victor Sebastian^{†,□}, Silvia Irusta^{†,□},
3 Manuel Arruebo^{†,□,*}, Jesus Santamaria^{†,□}, Pilar Martín Duque^{⊥,↵}

4 †Department of Chemical Engineering. Aragon Institute of Nanoscience (INA), University of
5 Zaragoza, Campus Río Ebro-Edificio I+D, C/ Poeta Mariano Esquillor S/N, 50018-Zaragoza, Spain

6 □Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN,
7 28029-Madrid, Spain.

8 ⊥Universidad Francisco de Vitoria, Facultad de Ciencias Biosanitarias, Carretera Pozuelo a
9 Majadahonda, Km 1.800, 28223 Pozuelo de Alarcón, Madrid, Spain

10 ↵Fundación Araid, Zaragoza, Spain

11 **Background:** In this study we investigated the ability of PEG functionalized gold nanoparticles
12 as non-viral vectors in the transfection of different cell lines, comparing them with commercial
13 lipoplexes.

14 **Methods:** Positively charged gold nanoparticles were synthesized using PEI as reducing and
15 stabilizer agent and its cytotoxicity reduced by its functionalization with PEG. We bound the
16 nanoparticles to three plasmids with different sizes (4-40 kpb). The vector internalization was
17 evaluated by confocal and electronic microscopy. Its transfection efficacy was studied by
18 fluorescence microscopy and flow cytometry. The application of the resulting vector in gene
19 therapy was indirectly evaluated using ganciclovir in HeLa cells transfected to express the
20 herpes virus thymidine kinase.

21 **Results:** An appropriate ratio between the nitrogen from the PEI and the phosphorous from
22 the phosphate groups of the DNA together with a reduced size and an elevated electrokinetic
23 potential are responsible for an increased nanoparticle internalization and enhanced protein
24 expression when carrying plasmids of up to 40kbp (plasmid size close to the limit of the DNA-
25 carrying capacity of viral vectors). Compared to a commercial transfection reagent, an equal or
26 even higher expression of reporter genes (on HeLa and HEK 293T) and suicide effect on HeLa
27 cells transfected with the herpes virus thymidine kinase gene were observed when using this
28 novel nanoparticulated vector.

29 **Conclusions:** Non-viral vectors based on gold nanoparticles covalently coupled with
30 polyethylene glycol (PEG) and Polyethylenimine (PEI) can be used as efficient transfection
31 reagents showing expression levels same or greater than the ones obtained with commercially
32 available lipoplexes.

33 **Keywords:** Transfection • nanobiotechnology • nanomedicine • gene therapy • vector
34 polymeric

35 **Introduction**

36 Nanoparticle-mediated transfection is characterized by a reduced immunogenicity and a low
37 production cost, and an easy and scalable synthesis process compared to the highly efficient
38 viral vectors (i.e., adenovirus, retrovirus, etc.). Endosomal escape, oligonucleotide protection
39 and efficient condensation and intracellular unpacking are the main drawbacks to overcome
40 when designing nanoparticulated transfection reagents. Not only nanoparticle diffusion but
41 also sedimentation influences cellular uptake which represents a very important parameter to
42 consider when carrying out *in vitro* studies¹. However, cellular uptake depends mainly on the
43 oligonucleotide loading on the surface of the nanoparticulated carrier². Gilleron et al.³
44 demonstrated *in vitro* and *in vivo* that only a small fraction of the siRNAs was able to escape
45 from the endosomes into the cytosol, when using lipid nanoparticles as short interfering siRNA
46 delivery vectors. This gene delivery efficiency can be improved by promoting endosomal
47 escape and by protecting the oligonucleotide from intra and extracellular degradation. Drugs,
48 peptides, lipids and cationic polymers have been added to nanoparticle-based formulations to
49 promote this endosomal escape⁴. The protection of the oligonucleotide of interest against
50 enzymatic nuclease degradation can be carried out by encapsulation inside the
51 nanoparticulated system⁵ or by means of layer-by-layer assembly of alternate polyelectrolytes
52 on the surface of the nanoparticles together with the plasmid or siRNA⁶. Finally, direct covalent
53 coupling of the oligonucleotide to the nanoparticle reduces the susceptibility to nuclease
54 degradation when the bond does not impair the oligonucleotide biological activity⁷. Those
55 benefits have supported several clinical trials using nanoparticles transporting plasmids⁸ and
56 siRNAs⁹ suppressing or silencing genes involved in cancer proliferation.

57 Rosi et al.⁷ demonstrated that with the same amount of antisense oligonucleotide transported,
58 gold nanoparticles can outperform the silencing efficiency in terms of protein percent
59 knockdown compared to different commercially available transfection reagents with no signs
60 of cytotoxicity at the doses tested. Lee et al.¹⁰ described the gene silencing efficiency of
61 cysteamine modified gold nanoparticles decorated with PEI and targeted using hyaluronic acid
62 using luciferase-specific siRNA and vascular endothelial growth factor-specific siRNA in the
63 presence of 50 vol % serum to simulate *in vivo* conditions. Under those conditions, a 70%
64 reduction of the VEGF mRNA level was measured for the nanoparticulated vector whereas only
65 a 20% reduction was observed for the commercial lipofectamine used as control. Simultaneous

66 co-delivery of si-RNA and plasmidic DNA for knockdown and expression was demonstrated by
67 Bishop et al.¹¹ using polymer-coated (by layer-by-layer) gold nanoparticles with superior
68 performance compared to commercially available transfection reagents at the same dosages in
69 human brain cancer cells.

70 However, even with higher transfer efficiency, strategies designed to improve the
71 oligonucleotide penetration and lower cytotoxicity are highly desired. To do so, strategies
72 using copolymers based on PEI (polyethylenimine) and PEG (polyethylene glycol) and linked
73 with cell penetrating peptides (i.e., trans-activating transcriptional activator TAT) have been
74 widely used as transfection reagents¹². For those polyplexes appropriate sizes (between 50 and
75 75 nm) and PEI nitrogen to DNA phosphates ratios (30-40) are critical to achieve high
76 transfection efficiency¹². The use of PEI and PEG as transfection reagents has also been
77 previously combined with magnetic nanoparticles. The conjugation of PEI to nanoparticles
78 favors DNA sedimentation and cellular uptake and enhances the transfection efficiency¹³. In
79 this regards Stephen et al.¹⁴ have recently showed the use of chitosan-PEG grafted with
80 catechol functionalized with cationic polyethylenimine on the surface of magnetic
81 nanoparticles. However, the transfection efficiency was reduced when PEG was used to reduce
82 the cytotoxicity of the transfection reagent. In addition, PEG and PEI have also been grafted on
83 the surface of carbon nanotubes¹⁵ and graphene¹⁶ to silence target gene expression via RNA
84 interference taking advantage of the improved solubility provided by the PEG.

85 In general PEG reduces non-specific interactions with plasma proteins and nanoparticle-cell
86 internalization with the consequent reduction in the transfection efficacy. Many PEG de-
87 shielding strategies have been implemented to release the plasmid *in vivo* under the
88 intracellular reductive conditions^{17,18}. Williams et al.¹⁹ demonstrated *in vivo* that neither the
89 covalent coupling nor the electrostatic interaction of gold nanoparticles to PEI/PEG increased
90 the transfection efficiency and protein expression compared to the levels achieved with the
91 PEI/PEG polyplexes alone. The authors postulated that the electrostatic interaction was not
92 stable enough during the delivery and for the case of the covalently grafted PEI/PEG, a low
93 nanoparticle to PEI/PEG ratio might be responsible for such a reduced transfection efficiency.

94 Here, we present a transfection reagent based on gold nanoparticles and PEG/PEI in which the
95 transfection efficiency levels reached are equivalent or even superior in some conditions to
96 commercially available transfection reagents using 3000, 4700 and up to 40000 base pairs
97 plasmids, the later being close to the limit of the DNA-carrying capacity of viral vectors²⁰.

98

99 **Materials and Methods**

100 **Nanoparticle Synthesis and Characterization**

101 Au-PEI nanoparticles were synthesized using Polyethylenimine (PEI) branched (≈ 25 kDa, Sigma
102 Aldrich) as reductant and stabilizer. Briefly, 1 mL of a 0.5×10^{-3} M PEI solution was added to 19
103 mL of a solution of 50 mgL^{-1} of HAuCl_4 at room temperature under vigorous stirring. The
104 resulting Au-PEI nanoparticles were dialyzed (50 kDa cut-off) against distilled water in order to
105 eliminate the unbound PEI. Those nanoparticles were subsequently bound to poly-ethylene
106 glycol (PEG) by using an excess of monofunctional poly(ethylene glycol)methyl-ether-thiol
107 (PEG, 800 Da MW Sigma Aldrich). Any excess of unbound PEG was removed by dialysis (14 kDa
108 cut-off).

109 Preliminary electron microscopy observations were carried out in LMA-INA-UNIZAR using a
110 T20-FEI microscope with a LaB6 electron source fitted with a "SuperTwin[®]" objective lens
111 allowing a point-to-point resolution of 2.4 Å. Aberration corrected scanning transmission
112 electron microscopy (Cs-corrected STEM) images were acquired using a high angle annular
113 dark field detector in a FEI XFEG TITAN electron microscope operated at 300 kV equipped with
114 a CETCOR Cs-probe corrector from CEOS Company allowing formation of an electron probe of
115 0.08 nm. The geometric aberrations of the probe-forming system were controlled to allow a
116 beam convergence of 24.7 mrad half angle to be elected. Phosphotungstic acid was used to
117 visualize PEG and PEI functionalization. The zeta potential and the particle-size distribution
118 were measured by dynamic light scattering (DLS) at pH=7 in a Brookhaven 90 Plus equipment
119 using the ZetaPals software. Also UV-visible spectroscopy (Jasco V670) was used for the
120 nanoparticle extinction spectrum evaluation. The bond between PEI, Au and PEG was studied
121 by Fourier transform infrared spectroscopy. Nitrogen (from PEI) to phosphorous (from
122 phosphate groups in the DNA) ratios were calculated using X-Ray photoelectron spectroscopy
123 (XPS) by using an Axis Supra (Kratos Analytical, UK). A monochromatic Al K α X-ray radiation ($h\nu$
124 = 1486.6 eV) was used as excitation source at 15 kV and 15 mA. The peaks analysis was
125 developed by the CasaXPS software (Casa Software Ltd, UK). In this analysis, the core level P
126 2p_{3/2} centered at 133.4 eV was attributed to the phosphate groups in the DNA in agreement
127 with the previous literature²².

128 **NPs/DNA complex formation and agarose gel electrophoresis retention assay**

129 Au-PEI and Au-PEI-PEG nanoparticles were complexed with DNA at different $\mu\text{g NPs}/\mu\text{g DNA}$
130 weight (w/w) ratios. The amount of DNA was kept constant (1 μg) and the nanoparticle mass
131 was varied from 10 to 50 μg in a final volume of 50 μL . The complexes were incubated for 30

132 min at room temperature. The DNA binding ability of the NPs was evaluated by using the
133 agarose gel electrophoresis retention assay. The loading buffer was mixed with the complexes
134 before adding them into 1% agarose gel containing SYBR® Safe stain. After running the gel at
135 60V for 40 min, the migration of plasmidic DNA was visualized in a UV chamber (Biorad
136 ChemiDoc RXS). Moreover, the DNA/NPs binding ability was analyzed measuring the surface
137 charge of the complexes by DLS in a Brookhaven 90 Plus apparatus.

138 In order to study the DNA protection capacity of the nanoparticles, the Au-PEI or Au-PEI-
139 PEG/DNA complexes were incubated with NotI and XhoI restriction enzymes during 1 hour at
140 37°C. The resulting digestion was added into a 1% agarose gel containing SYBR® Safe stain and
141 ran at 60V for 40 min. The migration of the fragment was visualized in a UV chamber (Biorad
142 ChemiDoc RXS).

143 **AFM analysis**

144 AFM measurements were made in liquid phase by the Quantitative Nanomechanical
145 Measurement Peakforce intermittent contact technique, in a Multimode 8 (Bruker Co.). The
146 applied force was 1nN and the tip used was a commercial tip (Bruker, SNL model, type – C),
147 with a hardness around 0.5N/m.

148 **Cell culture and nanoparticle cytotoxicity evaluation**

149 HeLa and HEK 293T cells were obtained from Cancer Research UK Culture Collection. Both
150 types of cells were cultured in Dulbecco's modified Eagle's (DMEM) with 10% fetal bovine
151 serum (FBS, GIBCO), 1% penicillin/streptomycin and 1% amphotericin and maintained at 37°C
152 in a 5% CO₂-humidified incubator. For the cytotoxicity experiments HeLa and HEK 293T cells
153 were seeded onto 96 multi well plates at 5×10^3 or 1×10^4 cells per well, respectively. The
154 toxicity of the different vectors (Au-PEI and Au-PEI-PEG nanoparticles) was evaluated by the
155 AlamarBlue® assay after 24 hours of incubation for different nanoparticle concentrations ($12,5$
156 $\mu\text{g mL}^{-1}$ to $100 \mu\text{g mL}^{-1}$).

157 **Confocal microscopy**

158 In order to assess the intracellular trafficking of the reporter gene pEGFP, confocal microscopy
159 was used. The pEGFP was labeled with Laber IT® μ Array Cy5 (Mirus) according to the
160 manufacturer's indications. For the DNA internalization assay cells were cultured on sterile
161 cover slips at 2×10^4 cells per dish before running confocal microscopy analysis. For that
162 purpose, 1 μg of labeled-pEGFP was complexed with 20 or 30 μg of Au-PEI-PEG nanoparticles
163 or with 3 μL of Lipofectamine® 2000 in 50 μL of DMEM. The complexes were incubated with

164 cells during 4 hours. Afterwards, cells were washed with PBS twice and fixed with 4% para-
165 formaldehyde during 20 min, followed by staining with phalloidin 488 to label the actin fibers
166 and the cell nucleus with DAPI. The intracellular localization of the resulting complexes inside
167 the cells was verified by using an Olympus Compact Type Oil FV10i confocal microscope.

168 **Transfection assays**

169 Three different plasmids were conjugated to Au-PEI-PEG nanoparticles: pEGFP, p Δ dTL and
170 pTK. pEGFP-N1 (Clontech Laboratories Inc.) is a 4.7 kbp plasmid that encodes the green
171 fluorescence protein under the CMV promoter. The Δ dTL was kindly provided by Ramón
172 Alemany (Bellvitge Biomedical Research Institute, Spain), this 41.9 kbp plasmid has the
173 inactivated genome of an oncolytic virus but also encodes a green fluorescence protein²³. pTK
174 was given by Jon Schoorlmmmer (Fundación Araid, Spain). This 5 kbp expression vector encodes
175 the herpes simplex virus thymidine kinase gene under the control of the thymidine kinase
176 promoter. EGFP and Δ dTL transfection efficiencies were evaluated by fluorescence microscopy,
177 whereas EGFP expression was also quantified by flow cytometry. In addition, TK expression
178 was indirectly measured studying the Ganciclovir cytotoxic effect in transfected cells, as it is
179 the prodrug that activates the TK's suicide effect. In all cases the ratio between NPs and DNA
180 was 20:1 and 30:1 w/w.

181 To carry out the fluorescence microscopy experiments, cells were seeded onto 96 multi well
182 plates at the densities mentioned above. 125 or 250 ng of pEGFP or p Δ dTL were added to
183 each well. First of all, the Au-PEI-PEG nanoparticles/DNA (20:1 and 30:1 w/w) or
184 Lipofectamine/DNA complexes were incubated with HeLa or HEK 293T cells during 24 or 48
185 hours. In the case of Lipofectamine® the culture medium was changed 4 hours after its
186 addition, and the Lipofectamine/DNA relation was 3:1 (v/w), as it is normally indicated for our
187 cell types. The green fluorescence was visualized using an Olympus IX81 inverted fluorescence
188 microscope. For the evaluation of the transfection efficiency using cytometry, cells were
189 seeded onto 6 multi well plates (1×10^5 cells per well). The transfection efficiency was
190 evaluated by flow cytometry using a FACSAria separator cytometer (BD) under a 488 nm laser
191 excitation. Cells were incubated with Au-PEI-PEG nanoparticles/DNA or Lipofectamine/DNA
192 complexes during 24 h or 48 h. Also in this case the medium of the cells treated with
193 Lipofectamine® was changed after 4 h. At the desired time points cells were harvested and
194 EGFP expression quantified.

195 To follow up the transfection effects with the plasmid encoding the thymidine kinase gene,
196 cells were incubated with the complexes during 24 hours. Then, DMEM containing 1 mg mL^{-1}

197 of Ganciclovir ((GCV), Sigma) was added to the cellular cultures. GCV is a pro-drug which exerts
198 antiproliferative effects in cells that express the thymidine kinase gene. Both types of cells
199 (HeLa and HEK 293T) were incubated with this GCV medium for 72 hours. Afterwards, an
200 AlamarBlue® assay was performed in order to analyze the cellular viability.

201 **Transmission electron microscopy**

202 In order to study the intracellular localization of Au-PEI and Au-PEI-PEG nanoparticles, HeLa
203 cells were seeded at a 1×10^6 cell per plate density onto a t75 flask and cultured for 24 hours.
204 At that time point a dispersion of DMEM containing $10 \mu\text{g mL}^{-1}$ of Au-PEI or Au-PEI-PEG
205 nanoparticles in a final volume of 10mL, was added to the culture. Cells were incubated with
206 this dispersion during 24 hours. After that time cells were washed twice with PBS and
207 trypsinized. The cellular pellet was fixed with 2,5% glutaraldehyde during 1h and washed again
208 twice with PBS. A post-fixation was performed for 1,5 h in 1% osmium tetroxide at room
209 temperature. The samples were washed several times before their dehydration in graded
210 series of ethanol (30, 50, 70, 95 and 100 vol.%) and propylene oxide. Both samples were then
211 embedded in Durcupan (Fluka, Sigma). Sections with a thickness of about 60 nm were
212 mounted on nickel grids before their examination by a T20-FEI microscope and by a FEI Titan
213 Cube 60-300 TEM operating in a STEM-HAADF mode.

214 **Statistical analysis**

215 Results are expressed as mean \pm SD. Statistical analysis was performed with the STATA
216 Software. Student's t-test was used to assess statistical differences ($p < 0.05$) between groups
217 with normal distribution and Kruskal-Wallis ($p < 0.05$) between groups with non-normal
218 distribution.

219 **Results**

220 **Nanoparticle synthesis and characterization**

221 Figure 1 describes the morphology of the nanoparticulated gene carriers here described. DLS
222 measurements revealed a hydrodynamic size distribution centered at $11,1 \pm 2$ nm and
223 histograms retrieved from the TEM size analysis on dried samples ($11,3 \pm 2$ nm) corroborated
224 those sizes. The polycrystalline structure of the nanocrystals can be observed in the HRTEM
225 images. Also an organic halo around the nanoparticles is indicative of the presence of the
226 polymeric PEI and PEG corona. The colloidal Au-PEI-PEG nanoparticles in water show a
227 maximum UVVIS extinction peak at around 520 nm (Figure S1). This absorption is characteristic
228 of the localized surface plasmon resonance peak of spherical gold nanocrystals due to the gold

229 interband transitions reached when the value of the real part of the dielectric function of the
230 particle material equals two times the dielectric constant of the solvent (water)²⁴. The high
231 extinction at low wavelengths observed is caused by the scattering of the samples. Zeta
232 potential analysis revealed a positive charge for the colloidal Au-PEI-PEG nanoparticles,
233 electrokinetic potential which was reduced after plasmid DNA (pEGFP) grafting but still
234 positive to be able to electrostatically interact with the negatively charged cell surface
235 glycoproteins. A reduced size (~5 times less) and higher zeta potential (~3 times more) was
236 observed for the Au-PEI-PEG nanoparticles compared to Lipofectamine® 2000 after DNA
237 coupling.

238 **Figure 1.** Au-PEI and Au-PEI-PEG nanoparticle characterization. a) Au-PEI (left) and Au-PEG-PEI (right)
239 nanoparticles TEM images (above) and STEM-HAADF image (bottom). The PEG corona is visible because
240 of the phosphotungstic acid staining (right). b) DLS analysis. Size of Lipofectamine and the nanoparticles
241 incubated with pEGFP. Zeta potential of the Au-PEI-PEG nanoparticles before and after GFP plasmid
242 coupling. The Z potential was measured at pH=7 in distilled water.

243 FTIR analysis (Figure SI1) was performed to evaluate the successful covalent coupling between
244 the SH-PEG and the gold nanoparticles and also to corroborate the presence of the amino
245 groups introduced by the PEI. SH-PEG exhibits the S–H stretching vibrational mode appearing
246 at around 2557 cm⁻¹. As expected, subsequent to its reaction with Au-PEI nanoparticles, the S–
247 H bond stretching vibrational band completely disappeared which indicated the formation of
248 the S–Au bond²⁵. This S–Au interaction is partially covalent (~35%) and mostly electrostatic
249 (~65%)²⁶. N–H bending and C–N stretching modes were observed near 1594 and 1120 cm⁻¹,
250 respectively. CH₂ bending modes and C–C stretching modes were also observed at 1454 and
251 1047 cm⁻¹, respectively. Two N–H stretching modes were detected for the primary amine
252 group near 3355 and 3277 cm⁻¹, and an overtone band near 3180 cm⁻¹ was also present. The
253 characteristic C–H stretching modes were observed between 3000 and 2700 cm⁻¹, with the
254 most intense band being centered near 2805 cm⁻¹. For Au-PEI nanoparticles the relative
255 intensity of the C–N stretching mode was diminished relative to that of the C–C stretching
256 modes.

257 XPS analysis (Table SI1) also revealed the presence of phosphorus on the Au-PEI-PEG
258 nanoparticles incubated with the DNA, revealing a N/P from phosphate ratio of 40,6 (Table
259 SI1). This high ratio is a guarantee of a successful transfection in agreement with the previous
260 literature^{12,13,27}.

261
262

263 DNA-nanoparticle complex formation and cytotoxicity evaluation

264 The agarose gel electrophoresis assay demonstrated nanoparticle/DNA electrostatic
265 complexation (Figure 2). A constant amount of different plasmid DNA was complexed with Au-
266 PEI or Au-PEI-PEG nanoparticles at different ratios of 50:1, 40:1, 30:1, 20:1 and 10:1
267 (nanoparticles:DNA). Maximum fluorescence signals were detected for the 20:1 and 30:1
268 samples, whereas at higher nanoparticle loadings the band was not clearly observed, probably
269 caused by the fluorescence quenching by nanoparticle agglomeration in agreement with the
270 previous literature²⁷. In order to demonstrate the presence of the DNA, we use, as control, a
271 1:1 ratio of NPs:DNA (Figure S12). In that large DNA excess, the genetic material was not totally
272 bound to the NPs, and a free DNA band was observed. Three different plasmids of different
273 number of base pairs (3000, 4700 and up to 40000 kbp) were successfully complexed by the
274 Au-PEI-PEG nanoparticles and no signs of plasmid fragmentation was observed.

275 Subcytotoxic doses for the Au-PEI and Au-PEI-PEG nanoparticles were evaluated on different
276 cell lines (HeLa and Hek293t) evaluating the resazurin colorimetric change in response to the
277 cellular metabolism (Figure 2). Following the recommendations of the ISO 10993-5 in which
278 viabilities higher than 70% are not considered cytotoxic we proposed the use in vitro of Au-PEI-
279 PEG nanoparticles at doses up to 50 µg/mL on Hek293t cells and up to 25 µg/mL on HeLa cells.
280 Our results indicated that doses below 12,5 µg/mL could be potentially used for transfection
281 applications on those cell lines when using just Au-PEI nanoparticles. Clearly PEGylation
282 reduced PEI cytotoxicity in agreement with the literature²⁸, probably caused by a reduced cell
283 internalization.

284 **Figure 2.** Biological characterization of Au-PEI and Au-PEI-PEG nanoparticles. a) Agarose gel
285 electrophoresis for different Au-PEI and Au-PEI-PEG/plasmid ratios (w/w) The amount of DNA was kept
286 constant and the amount of nanoparticles was increased from 10 to 50 µg. b) Cytotoxicity evaluation of
287 Au-PEI an Au-PEI-PEG nanoparticles in HeLa and HEK 293T cells by using the AlamarBlue assay. The
288 toxicity was calculated relative to an untreated control for which 100% viability was set.

289 We also analyzed the DNA protection from degradation by using a gel retardation assay. Naked
290 DNA showed degradation after treatment with the XhoI and NotI restriction enzymes (Figure
291 S13). In contrast, no significant loss of plasmid integrity was observed for the nanoparticulated
292 complexes, indicative of a successful DNA condensation and protection in the polymeric
293 nanoparticle corona. DNA condensation was also corroborated by AFM (see Figure S14) where
294 a slight nanoparticle size increase was observed for the Au-PEI-PEG nanoparticles after DNA
295 coupling and no free DNA was observed.

296 **Transfection efficiency**

297 We observed how GFP expression was qualitatively enhanced when using both Au-PEI-PEG
298 20:1 and 30:1 (w/w) transfection reagents compared to the commercial liposomal formulation
299 (Figure 3) in both HeLa and Hek293t cell lines. Bright field images show that the morphology of
300 the cell lines was not altered by the presence of the nanoparticles. HeLa cells remained
301 elongated, growing adherently with epithelial morphology. Hek293t cells also remained
302 unaltered showing an epithelial adherent morphology.

303 **Figure 3.** pEGFP transfection evaluation by fluorescence microscopy in HeLa and HEK 293T cells. GFP
304 fluorescence was evaluated at 488/520 nm excitation/emission. All the images were acquired with the
305 10X objective 24 h after the addition of the complexes in a fluorescence inverted microscopy Olympus
306 IX81. Scale: 200 micron. Cells not incubated with any vector were used as negative control, while cells
307 incubated with Lipofectamine/pEGFP complexes were used as positive control.

308 Figure 4 shows the fluorescence quantification by flow cytometry from cells expressing the
309 gene for green fluorescent protein (GFP) using the nanoparticles and the commercial
310 Lipofectamine® 2000. Similar results were obtained 24h after transfection but 48h later the
311 green fluorescence intensity was higher ($p < 0.05$) when using Au-PEI-PEG nanoparticles
312 compared to the control. The percentage of GFP positive cells 48 h after the addition of the
313 complexes was approximately a 15% higher for the 20:1 ratio than for the Lipofectamine-
314 based control and for the 30:1 ratio, the percentage of GFP positive cells 48 h after the
315 addition of the complexes was a 20% higher than that obtained for the control.

316 **Figure 4.** Fluorescence quantification by flow cytometry in HeLa and HEK 293T cells. The cytometry
317 graphs show the GFP positive cells at 48 h. Statistically significant differences are labelled with *. ($p <$
318 0.05). Positive control represents the use of Lipofectamine® 2000. Cells not incubated with any vector
319 were used as negative control.

320 A successful transfection was even achieved using the Au-PEI-PEG nanoparticles as gene
321 carriers of a 40000 base pairs plasmid (Figure 5). Qualitatively a higher transfection was
322 achieved when using the gold-based nanocarriers. The transfection efficiency of large plasmids
323 is limited by the slow transit through the intracellular vesicles by molecular crowding and small
324 plasmids are usually diffusing faster towards the nuclei^{29,30}.

325

326

327 **Figure 5.** pAdTL transfection evaluation by fluorescence microscopy on HEK 293T cells. The images were
328 taken in a fluorescence inverted microscopy Olympus IX81. All the images were acquired with the 10X
329 objective 24 h after the addition of the complexes. In these cases two amounts of DNA were tested: 125
330 and 250 µg per well. Scale bar: 200 micron. Cells not incubated with any vector were used as negative
331 control, while cells incubated with Lipofectamine/pAdTL complexes were used as positive control.

332 As one of the main purposes of this strategy would be the use of those NPs as vectors for gene
333 therapy, we performed a classical approach of suicide gene therapy mediated by the Herpes
334 Simplex virus thymidine kinase gene triggered by the prodrug Ganciclovir. The gene product
335 phosphorylates the nontoxic GCV into GCV triphosphate, which is incorporated into DNA in
336 replicating cells, inhibiting DNA synthesis and resulting in cell death³¹. Figure 6 shows the
337 enhanced transgene efficient delivery when using the Au-PEI-PEG nanoparticles compared to
338 the use of the commercial formulation.

339 **Figure 6.** Cell viability using the thymidine kinase suicide gene under the presence of GCV in HeLa cells.
340 Phosphorilated GCV is able to mediate the cell death at the doses studied. In the maximum nanoparticle
341 concentration the high presence of Au-PEI-PEG nanoparticles promote some death in the absence of
342 GCV.

343 Intracellular trafficking was monitored using Cy5 labeled-pEGFP complexed with either Au-PEI-
344 PEG nanoparticles or with Lipofectamine® 2000. As can be seen in Figure 7, after 4 hours of
345 incubation complexes were visible in the cytoplasm of the HeLa cells. The presence of
346 lipofectamine/Cy5-DNA complexes in the extracellular matrix clearly indicated the presence of
347 larger agglomerates compared to the ones observed when using the nanoparticulated gene
348 carriers. The orthogonal projections of the confocal images clearly show that some labeled
349 plasmids are located inside of the nuclei of the cells. The internalization of types of
350 nanoparticles was also evaluated by HRTEM in HeLa cells. Figure 8 shows the intracellular
351 distribution of both types of nanoparticles inside the cell cytosol. After 24 h of incubation, the
352 nanoparticles were accumulated forming aggregates within intracellular vesicles without
353 reaching the cellular nucleus.

354 **Figure 7.** Internalization complexes evaluation by confocal microscopy. Intracellular trafficking of
355 fluorescently (Cy5) labeled GFP plasmid bound to either Lipofectamine® or Au-PEI-PEG nanoparticles
356 after 4 hours of incubation. HeLa cells were fixed and visualized by confocal microscopy. Actin fibers are
357 shown in green and nuclei in cyan. The labelled plasmid DNA is shown in blue. Scale: 20 micron.

358

359

360 **Figure 8.** Internalization nanoparticle evaluation by TEM. Intracellular internalization of Au-PEI (above)
361 and Au-PEI-PEG (bottom) nanoparticles evaluated by STEM-HAADF. HeLa cells were incubated with Au-
362 PEI (above) or Au-PEI-PEG (bottom) during 24 h, the arrows indicate the presence of the nanoparticles
363 and their intracellular presence within vesicles. The presence of gold was confirmed in both cases by
364 EDX analysis.

365 **Discussion**

366 The transfection efficiency of nanoparticulated carriers can be improved when combining an
367 adequate electrokinetic potential, able to electrostatically bind condensed DNA, with
368 appropriate gene-vector dispersion and reduced agglomeration in the culture media. PEI
369 provides with the surface charge needed for a successful transfection due to its large buffering
370 and endosomolytic ability and PEG provides with a reduced unspecific adsorption and steric
371 hindrance. However this PEI buffering ability and consequent change in the endosomal pH is
372 still a matter of debate³² and probably its degradative action on the pH-dependent endosomal
373 compartment is responsible for the DNA release. Despite the successful transfection efficiency
374 of PEI, this cationic macromolecule acts as an apoptotic agent disrupting the plasma
375 membrane and altering the mitochondrial membrane³³. As we mentioned before, PEG has
376 been introduced in PEI-based vectors to improve their solubility and to reduce their
377 cytotoxicity but with the main drawback of reducing the efficiency compared to the one
378 achieved with the non-PEGylated vector. The reduction in the cytotoxicity induced by the PEG
379 is attributed to its mitigation ability to the charge-induced toxicity¹⁴. This charge reduction
380 decreases the PEI buffering ability and also the successive washing steps followed to anchor
381 PEG on the PEI-based vector contribute to remove unbound PEI which contributes to an
382 efficient gene expression³⁴. We clearly demonstrate (Figure 3) that PEG reduces the PEI
383 cytotoxicity probably caused by a reduction in the negative charge considering that the
384 electrokinetic potential of Au-PEI in water was $+30,4 \pm 0,8$ mV and after PEG grafting the Au-PEI-
385 PEG nanoparticles showed a zeta potential of $+26,2 \pm 2,4$ mV (Figure 1). Enzymatic degradation
386 is not responsible for a successful gene transfer carried out by the nanoparticulated systems.
387 We observed that no significant loss of plasmid integrity was observed after treating the
388 nanoconjugated plasmids with restriction enzymes. This is an indication that just PEI is a
389 successful reagent to condense plasmid DNA protecting it from degradation in the cytosol by
390 achieving a more stable form and with longer retention times than free DNA³⁵. It has been
391 postulated that PEI offers a steric and/or electrostatic barrier to the diffusion of the restriction
392 enzyme towards the protected DNA³⁶. The different transfection levels achieved for the two
393 cell lines tested might be attributed to the different cell-specific intracellular barriers for the

394 plasmid to overcome and to the different transcription efficiency and consequent protein
395 expression. It has been reported that Hek293t cells exhibit the highest level of PEI-mediated
396 GFP transfection with 50-80% of cells showing protein expression³⁷. The obtained gene
397 expression levels on HeLa cells were lower than the ones obtained with Hek293t cells (Figures
398 3 and 4), which can be attributed to the higher cytotoxicity of the Au-PEI-PEG nanoparticles on
399 the HeLa cells at the same doses (Figure 3). In addition, the 293t cell line contains the SV40
400 Large T-antigen which allows for episomal replication of transfected plasmids containing SV40
401 as the pEGFP used in this work²⁹. For that reason the amplification product might have a larger
402 temporal expression in the Hek293t cell line.

403 Lukacs et al.³⁸ demonstrated that plasmid DNA with sizes above 250 bp remain almost
404 immobile in the cytoplasm because of molecular crowding; however PEI has demonstrated
405 efficient transfection of large plasmids being able to unpack and release the DNA which then
406 diffuses to the nuclei. Large plasmid DNA (52.5 Kbp) rendered unsuccessful transfection
407 efficiency when using lipoplexes due to the incipient colloidal instability being the size and
408 morphology of the polyplex invariant irrespective of the plasmid size³⁰. Viral vectors have been
409 used linked to PEI to enhance transfection efficiency when using “large” plasmids. In this
410 regard, 12 Kbp plasmids have been linked to PEI and to an adenovirus for a successful
411 transfection of human primary myoblasts³⁹. In our work, we demonstrated how qualitatively a
412 superior gene expression was achieved when using Au-PEI-PEG nanoparticles compared to the
413 use of the commercial lipoplexe carrying a 40 Kbp plasmid. This efficiency difference might be
414 attributed to the PEG ability in retarding endosomal escape as previously reported⁴⁰.

415 Particle size affects gene expression and a reduced gene vector agglomeration in the culture
416 media favors DNA internalization. Large agglomerates sediment and interact easily with the
417 cellular membrane; however larger agglomerates are excluded from the endocytic route and
418 are usually internalized following macropinocytosis in which the internalized cargo is stored in
419 the lysosomal compartment⁴¹. Therefore, we propose that the lack of large agglomerates with
420 sizes above 200 nm (which is the optical resolution of the confocal microscope used) are
421 responsible of a successful transfection efficiency for our Au-PEI-PEG nanocarriers compared
422 to the Lipofectamine 2000 reagent where clear plasmid agglomerates were observed in the
423 culture media (Figure 7).

424 **Conclusions**

425 Gold nanoparticles can be used as non-viral vectors for gene expression using PEI as surface
426 functional agent. PEI condensates and protects the carried plasmid from enzymatic

427 degradation. The PEGylation of those nanoparticles by covalent coupling reduces the PEI
428 cytotoxicity as well as enhances nanoparticle dispersion in culture media. Different plasmids
429 with different number of pair bases can be transfected using this vector and plasmids up to
430 40kpb can be transfected with a superior performance than the one obtained with
431 commercially available lipoplexes. Not only reporter genes but also a superior suicide effect in
432 cells transfected with the herpes virus thymidine kinase gene mediated by ganciclovir was
433 observed using the nanoparticulated vector.

434 **Acknowledgements**

435 The financial support of the EU thanks to the ERC Consolidator Grant program (ERC-2013-CoG-
436 614715, NANOHEDONISM) is gratefully acknowledged. CIBER-BBN is an initiative funded by the
437 VI National R&D&i Plan 2008–2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions
438 and financed by the Instituto de Salud Carlos III (Spain) with assistance from the European
439 Regional Development Fund. The authors declare no conflict of interest.

440 **References**

- 441 1. Cho EC, Zhang Q, Xia Y. The Effect of Sedimentation and Diffusion on Cellular Uptake of
442 Gold Nanoparticles. *Nat Nanotechnol.* 2011;6(6):385-391. doi:10.1038/nnano.2011.58.
- 443 2. Giljohann DA, Seferos DS, Patel PC, Millstone JE, Rosi NL, Mirkin CA. Oligonucleotide
444 Loading Determines Cellular Uptake of DNA-Modified Gold Nanoparticles. *Nano Lett.*
445 2007;7(12):3818-3821.
- 446 3. Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle-
447 mediated siRNA delivery, intracellular trafficking and endosomal escape. *Nat*
448 *Biotechnol.* 2013;31(7):638-646. doi:10.1038/nbt.2612.
- 449 4. Cheng CJ, Tietjen GT, Saucier-Sawyer JK, Saltzman WM. A holistic approach to targeting
450 disease with polymeric nanoparticles. *Nat Rev Drug Discov.* 2015;14(4):239-247.
451 doi:10.1038/nrd4503.
- 452 5. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr at V. PLGA-based
453 nanoparticles: An overview of biomedical applications. *J Control Release.*
454 2012;161(2):505-522. doi:10.1016/j.jconrel.2012.01.043.
- 455 6. Han L, Zhao J, Zhang X, et al. Enhanced siRNA delivery and silencing gold-chitosan
456 nanosystem with surface charge-reversal polymer assembly and good biocompatibility.
457 *ACS Nano.* 2012;6(8):7340-7351. doi:10.1021/nn3024688.

- 458 7. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AKR, Han MS, Mirkin CA.
459 Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation. *Science*
460 (80-). 2006;312:1027-1030.
- 461 8. Senzer N, Nemunaitis J, Nemunaitis D, et al. Phase I study of a systemically delivered
462 p53 nanoparticle in advanced solid tumors. *Mol Ther*. 2013;21(5):1096-1103.
463 doi:10.1038/mt.2013.32.
- 464 9. Taberero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference
465 therapeutic targeting VEGF and KSP in cancer patients with liver involvement. *Cancer*
466 *Discov*. 2013;3(4):406-417. doi:10.1158/2159-8290.CD-12-0429.
- 467 10. Lee MY, Park SJ, Park K, Kim KS, Lee H, Hahn SK. Target-specific gene silencing of layer-
468 by-layer assembled gold-cysteamine/siRNA/PEI/HA nanocomplex. *ACS Nano*.
469 2011;5(8):6138-6147. doi:10.1021/nn2017793.
- 470 11. Bishop CJ, Tzeng SY, Green JJ. Degradable polymer-coated gold nanoparticles for co-
471 delivery of DNA and siRNA. *Acta Biomater*. 2015;11(1):393-403.
472 doi:10.1016/j.actbio.2014.09.020.
- 473 12. Ulasov A V, Khramtsov Y V, Trusov G a, Rosenkranz A a, Sverdlov ED, Sobolev AS.
474 Properties of PEI-based polyplex nanoparticles that correlate with their transfection
475 efficacy. *Mol Ther*. 2011;19(1):103-112. doi:10.1038/mt.2010.233.
- 476 13. Thomas M, Klibanov AM. Conjugation to gold nanoparticles enhances
477 polyethylenimine's transfer of plasmid DNA into mammalian cells. *Proc Natl Acad Sci U*
478 *S A*. 2003;100(16):9138-9143. doi:10.1073/pnas.1233634100.
- 479 14. Stephen Z, Dayringer C, Lim J, et al. An Approach to Rapid Synthesis and
480 Functionalization of Iron Oxide Nanoparticles for High Gene Transfection. *ACS Appl*
481 *Mater Interfaces*. 2016;8:6320-6328. doi:10.1021/acsami.5b10883.
- 482 15. Taghavi S, HashemNia A, Mosaffa F, Askarian S, Abnous K, Ramezani M. Preparation
483 and evaluation of polyethylenimine-functionalized carbon nanotubes tagged with 5TR1
484 aptamer for targeted delivery of Bcl-xL shRNA into breast cancer cells. *Colloids Surfaces*
485 *B Biointerfaces*. 2016;140(2016):28-39. doi:10.1016/j.colsurfb.2015.12.021.
- 486 16. Wang C, Wang X, Lu T, et al. Multi-functionalized graphene oxide complex as a plasmid
487 delivery system for targeting hepatocellular carcinoma therapy. *RSC Adv*.

- 488 2016;6(27):22461-22468. doi:10.1039/C5RA21475K.
- 489 17. Zhu H, Dong C, Dong H, et al. Cleavable PEGylation and Hydrophobic Histidylation of
490 Polylysine for siRNA Delivery and Tumor Gene Therapy. *ACS Appl Mater Interfaces*.
491 2014;6:10393-10407.
- 492 18. Noga M, Edinger D, Kläger R, et al. The effect of molar mass and degree of
493 hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-
494 coated polyplexes. *Biomaterials*. 2013;34(10):2530-2538.
495 doi:10.1016/j.biomaterials.2012.12.025.
- 496 19. Williams JH, Schray RC, Sirsi SR, Lutz GJ. Nanopolymers improve delivery of exon
497 skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of
498 mdx mice. *BMC Biotechnol*. 2008;8:35. doi:10.1186/1472-6750-8-35.
- 499 20. Friedmann T. Overcoming the Obstacles to Gene Therapy. *Sci Am*. 1997:96-101.
- 500 21. Cho EC, Zhang Q, Xia Y. The effect of sedimentation and diffusion on cellular uptake of
501 gold nanoparticles. *Nat Nano*. 2011;6(6):385-391.
502 <http://dx.doi.org/10.1038/nnano.2011.58>.
- 503 22. Gomes PJ, Ferraria AM, Botelho Do Rego AM, Hoffmann S V., Ribeiro PA, Raposo M.
504 Energy thresholds of DNA damage induced by UV radiation: An XPS study. *J Phys Chem*
505 *B*. 2015;119(17):5404-5411. doi:10.1021/acs.jpcc.5b01439.
- 506 23. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity
507 of adenoviral vectors. *Gene Ther*. 2001;8(2001):1347-1353. doi:10.1038/sj.gt.3301515.
- 508 24. Rodríguez-González B, Sánchez-Iglesias A, Giersig M, Liz-Marzán LM. AuAg bimetallic
509 nanoparticles: formation, silica-coating and selective etching. *Faraday Discuss*.
510 2004;125:133-144. doi:10.1039/b303205a.
- 511 25. Álvarez-Puebla RA, Contreras-Cáceres R, Pastoriza-Santos I, Pérez-Juste J, Liz-Marzán
512 LM. Au@pNIPAM colloids as molecular traps for surface-enhanced, spectroscopic,
513 ultra-sensitive analysis. *Angew Chemie - Int Ed*. 2009;48(1):138-143.
514 doi:10.1002/anie.200804059.
- 515 26. Ding Y, Jiang Z, Saha K, et al. Gold nanoparticles for nucleic acid delivery. *Mol Ther*.
516 2014;22(6):1075-1083. doi:10.1038/mt.2014.30.

- 517 27. Cheang T yun, Tang B, Xu A wu, et al. Promising plasmid DNA vector based on
518 APTEsmodified silica nanoparticles. *Int J Nanomedicine*. 2012;7:1061-1067.
519 doi:10.2147/IJN.S28267.
- 520 28. Wen S, Zheng F, Shen M, Shi X. Surface modification and PEGylation of branched
521 polyethyleneimine for improved biocompatibility. *J Appl Polym Sci*. 2013;128(6):3807-
522 3813. doi:10.1002/app.38444.
- 523 29. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein
524 production by transient transfection of suspension-growing human 293-EBNA1 cells.
525 *Nucleic Acids Res*. 2002;30(2):E9.
- 526 30. Kreiss P, Cameron B, Rangara R, et al. Plasmid DNA size does not affect the
527 physicochemical properties of lipoplexes but modulates gene transfer efficiency.
528 *Nucleic Acids Res*. 1999;27(19):3792-3798.
529 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC148641/>.
- 530 31. Barese CN, Krouse AE, Metzger ME, et al. Thymidine Kinase Suicide Gene-mediated
531 Ganciclovir Ablation of Autologous Gene-modified Rhesus Hematopoiesis. *Mol Ther*.
532 2012;20(10):1932-1943. doi:10.1038/mt.2012.166.
- 533 32. Benjaminsen R V, Matthebjerg M a, Henriksen JR, Moghimi SM, Andresen TL. The
534 possible "proton sponge " effect of polyethylenimine (PEI) does not include change in
535 lysosomal pH. *Mol Ther*. 2013;21(1):149-157. doi:10.1038/mt.2012.185.
- 536 33. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage
537 poly(ethylenimine)-mediated cytotoxicity: Implications for gene transfer/therapy. *Mol*
538 *Ther*. 2005;11(6):990-995. doi:10.1016/j.ymthe.2005.02.010.
- 539 34. Boeckle S, von Gersdorff K, van der Piepen S, Culmsee C, Wagner E, Ogris M.
540 Purification of polyethylenimine polyplexes highlights the role of free polycations in
541 gene transfer. *J Gene Med*. 2004;6(10):1102-1111. doi:10.1002/jgm.598.
- 542 35. Oh Y-K, Suh D, Kim JM, Choi H-G, Shin K, Ko JJ. Polyethylenimine-mediated cellular
543 uptake, nucleus trafficking and expression of cytokine plasmid DNA. *Gene Ther*.
544 2002;9(23):1627-1632. doi:10.1038/sj.gt.3301735.
- 545 36. Godbey WT, Barry MA, Saggau P, Wu KK, Mikos AG. Poly(ethylenimine)-mediated
546 transfection: a new paradigm for gene delivery. *J Biomed Mater Res*. 2000;51(3):321-

- 547 328.
- 548 37. Huh SH, Do HJ, Lim HY, et al. Optimization of 25 kDa linear polyethylenimine for
549 efficient gene delivery. *Biologicals*. 2007;35(3):165-171.
550 doi:10.1016/j.biologicals.2006.08.004.
- 551 38. Lukacs GL, Haggie P, Seksek O, Lechardeur D, Freedman N, Verkman AS. Size-dependent
552 DNA mobility in cytoplasm and nucleus. *J Biol Chem*. 2000;275(3):1625-1629.
- 553 39. Campeau P, Chapdelaine P, Massie B, Tremblay JP. Transfection of large plasmids in
554 primary human myoblasts. *Gene Ther*. 2001;8:1387-1394.
- 555 40. Zhang Y, Hu L, Yu D, Gao C. Influence of silica particle internalization on adhesion and
556 migration of human dermal fibroblasts. *Biomaterials*. 2010;31(32):8465-8474.
557 doi:10.1016/j.biomaterials.2010.07.060.
- 558 41. Stern ST, Adisheshaiah PP, Crist RM. Autophagy and lysosomal dysfunction as emerging
559 mechanisms of nanomaterial toxicity. *Part Fibre Toxicol*. 2012;9(1):20.
560 doi:10.1186/1743-8977-9-20.
- 561 42. Sokolov K, Follen M, Aaron J, et al. Real-time vital optical imaging of precancer using
562 anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles.
563 *Cancer Res*. 2003;63(9):1999-2004.
- 564 43. Kattumuri V, Katti K, Bhaskaran S, et al. Gum Arabic as a Phytochemical Construct for
565 the Stabilization of Gold Nanoparticles: In Vivo Pharmacokinetics and X-ray-Contrast-
566 Imaging Studies. *Small*. 2007;3(2):333-341. doi:10.1002/sml.200600427.
- 567 44. Zhang Q, Iwakuma N, Sharma P, et al. Gold nanoparticles as a contrast agent for in vivo
568 tumor imaging with photoacoustic tomography. *Nanotechnology*. 2009;20(39):395102.
569 doi:10.1088/0957-4484/20/39/395102.

570

571

572

573 **Table 1.** XPS elemental composition of the Au-PEI-PEG and Au-PEI-PEG-pDNA
574 nanoparticles. N/P from phosphate ratio after plasmid electrostatic binding.

575

	B.E. (eV)						N/P
	Atomic %						
	O 1s	Au 4f	N 1s	C 1s	S 2p	P 2p	
Au-PEI-PEG	531.7 11.21%	83.3 0.21%	398.2 15.19%	284.9 72.87%	162.4 0.51%	-	-
Au-PEI-PEG- pEGFP	531.8 9.99%	83.7 0.21%	398.6 17.07%	284.9 71.95%	167.3 0.36%	133.4 0.42%	40.6

576

577

578

579

580

581

582

583

584

585

586

587

588


589

590

591


592

593



c)



	Size (nm)	Z Potential (mV)
Lipofectamine 2000	109,6	36,5±3,78
Lipo_pEGFP 1:3	516±45,85	6,48±0,49
AuPEI-pEGFP 20:1	86,97±2,19	12,8±0,86
AuPEI-pEGFP 30:1	101,9±4,81	17,5±0,78
AuPEIPEG-pEGFP 20:1	125,7 ± 8,78	17,3±2,61
AuPEIPEG-pEGFP 30:1	123,3±3,26	19,1±0,95



595

596

597



599

600

601

602

603

604

605

606


607

608

609

610

611 **Figure 3.**



612

613

614

615

616

617

618




619

620

621

622

623 **Figure 4.**



624

625

626

627

628

629

630

631


632

633

634

635 **Figure 5.**

636



637

638

639

640

641

642

643

644

645

646

647


648

649

650

651 **Figure 6.**

652



653

654

655

656

657

658

659

660

661

662


663

664

665

666

667 **Figure 7.**



668

669

670

671

672


673

674

675

676

677 **Figure 8.**



678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693